Revolution Medicines to Participate in Upcoming Investor Conferences
Revolution Medicines (Nasdaq: RVMD), a clinical-stage oncology company focused on RAS-addicted cancers, announces its participation in two major healthcare conferences. CEO Mark A. Goldsmith will present at Guggenheim's Inaugural Healthcare Innovation Conference on November 12, 2024, at 3:00 p.m. ET in Boston, and the UBS Global Healthcare Conference on November 13, 2024, at 5:00 p.m. ET in Rancho Palos Verdes. Both presentations will be available via webcast on the company's website, with replays accessible for at least 14 days after the events.
Revolution Medicines (Nasdaq: RVMD), un'azienda oncologica in fase clinica focalizzata sui tumori dipendenti da RAS, annuncia la sua partecipazione a due importanti conferenze sanitarie. Il CEO Mark A. Goldsmith presenterà al Guggenheim's Inaugural Healthcare Innovation Conference il 12 novembre 2024, alle 15:00 ET a Boston, e al UBS Global Healthcare Conference il 13 novembre 2024, alle 17:00 ET a Rancho Palos Verdes. Entrambe le presentazioni saranno disponibili tramite webcast sul sito web dell'azienda, con le registrazioni accessibili per almeno 14 giorni dopo gli eventi.
Revolution Medicines (Nasdaq: RVMD), una empresa oncológica en fase clínica centrada en cánceres adictos a RAS, anuncia su participación en dos importantes conferencias de salud. El CEO Mark A. Goldsmith presentará en la Guggenheim's Inaugural Healthcare Innovation Conference el 12 de noviembre de 2024, a las 3:00 p.m. ET en Boston, y en la UBS Global Healthcare Conference el 13 de noviembre de 2024, a las 5:00 p.m. ET en Rancho Palos Verdes. Ambas presentaciones estarán disponibles a través de un webcast en el sitio web de la empresa, con repeticiones accesibles durante al menos 14 días después de los eventos.
Revolution Medicines (Nasdaq: RVMD)는 RAS에 의존하는 암에 집중하는 임상 단계의 종양학 회사로, 두 개의 주요 의료 회의에 참여한다고 발표했습니다. CEO Mark A. Goldsmith는 2024년 11월 12일 오후 3시 ET에 보스턴에서 열리는 구겐하임의 첫 번째 의료 혁신 회의에서 발표하며, 2024년 11월 13일 오후 5시에 랜초 팔로스 베르데스에서 열리는 UBS 글로벌 의료 회의에서도 발표할 예정입니다. 두 프레젠테이션 모두 회사 웹사이트를 통해 웹캐스트로 제공되며, 이벤트 후 최소 14일 동안 재생이 가능합니다.
Revolution Medicines (Nasdaq: RVMD), une entreprise d'oncologie en phase clinique axée sur les cancers dépendants de RAS, annonce sa participation à deux grandes conférences sur la santé. Le PDG Mark A. Goldsmith présentera à la Guggenheim's Inaugural Healthcare Innovation Conference le 12 novembre 2024 à 15h00 ET à Boston, et à la UBS Global Healthcare Conference le 13 novembre 2024 à 17h00 ET à Rancho Palos Verdes. Les deux présentations seront disponibles en webcast sur le site web de l'entreprise, avec des rediffusions accessibles pendant au moins 14 jours après les événements.
Revolution Medicines (Nasdaq: RVMD), ein in der klinischen Phase befindliches Onkologieunternehmen, das sich auf RAS-abhängige Krebserkrankungen konzentriert, gibt seine Teilnahme an zwei wichtigen Gesundheitskongressen bekannt. CEO Mark A. Goldsmith wird am 12. November 2024 um 15:00 Uhr ET auf der Guggenheim's Inaugural Healthcare Innovation Conference in Boston und am 13. November 2024 um 17:00 Uhr ET auf der UBS Global Healthcare Conference in Rancho Palos Verdes präsentieren. Beide Präsentationen werden über einen Webcast auf der Unternehmenswebsite verfügbar sein, und die Aufzeichnungen sind mindestens 14 Tage nach den Veranstaltungen zugänglich.
- None.
- None.
REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at Guggenheim's Inaugural Healthcare Innovation Conference and the UBS Global Healthcare Conference.
Details of the company’s participation are as follows:
- Guggenheim's Inaugural Healthcare Innovation Conference
Conference Dates: November 11-13, 2024
Fireside Chat Time/Date: 3:00 p.m. ET on Tuesday, November 12, 2024
Location: Boston, MA; webcast available
- UBS Global Healthcare Conference
Conference Dates: November 11-14, 2024
Fireside Chat Time/Date: 5:00 p.m. ET on Wednesday, November 13, 2024
Location: Rancho Palos Verdes, CA; webcast available
To access the live webcasts, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of the webcasts will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C), in addition to RAS companion inhibitors RMC-4630 and RMC-5552.
FAQ
When is Revolution Medicines (RVMD) presenting at the Guggenheim Healthcare Conference in 2024?
Where can I watch Revolution Medicines' (RVMD) healthcare conference webcasts in November 2024?
What healthcare conferences is Revolution Medicines (RVMD) attending in November 2024?
